Skip to main content

Advertisement

SpringerLink
Log in

Skin Cancer and the Solid Organ Transplant Recipient

  • Melanoma and Skin Tumors
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Organ transplant recipients (OTRs) are living longer in setting of improved medical immunosuppression. The most common late post-transplant complication includes a variety of malignant and premalignant cutaneous tumors. Aggressive skin cancers are common in this population. Clinical and pathologic correlation is essential in choosing the appropriate treatment for the various subtypes of skin cancer in OTR. Approaches include risk assessment for other skin tumors, treatment of malignancy, and prevention. Few prospective or retrospective studies with multivariate analysis exist and therefore opinion largely dominates treatment recommendations. Treatment aims: (i) The mainstay of treatment focuses on total removal (excision) or mechanical destruction of the tumor. In the appropriate clinical scenario, a skin cancer should be removed or treated fully. (ii) Treatment modality is dependant upon low- vs high-risk tumors and tumor type. (iii) Utilize excision with margin control, either by permanent or frozen (Mohs) technique, for large tumors and tumors in high-risk sites. (iv) New treatment modalities include immune modulators, topical photodynamic therapy, and drugs targeting genetic defects. (v) Education on skin cancer prevention should target all the age groups.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Housman TS, Williford PM, Feldman SR, et al. Nonmelanoma skin cancer: an episode of care management approach. Dermatol Surg 2003;29:700–711. doi:10.1046/j.1524-4725.2003.29185.x.

    Article  PubMed  Google Scholar 

  2. Housman TS, Feldman SR, Williford PM, et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol 2003;48:425–429. doi:10.1067/mjd.2003.186.

    Article  PubMed  Google Scholar 

  3. Dapprich DC, Weenig RH, Rohlinger AL, et al. Outcomes of melanoma in recipients of solid organ transplant. J Am Acad Dermatol 2008;59:405–417. doi:10.1016/j.jaad.2008.05.015.

    Article  PubMed  Google Scholar 

  4. Andruchow JL, Veness MJ, Morgan GJ, et al. Implications for clinical staging of metastatic cutaneous squamous carcinoma of the head and neck based on a multicenter study of treatment outcomes. Cancer 2006;106:1078–1083. doi:10.1002/cncr.21698.

    Article  PubMed  Google Scholar 

  5. O’Brien CJ. The parotid gland as a metastatic basin for cutaneous cancer. Arch Otolaryngol Head Neck Surg 2005;131:551–555. doi:10.1001/archotol.131.7.551.

    Article  PubMed  Google Scholar 

  6. O’Brien CJ, McNeil EB, McMahon JD, et al. Significance of clinical stage, extent of surgery, and pathologic findings in metastatic cutaneous squamous carcinoma of the parotid gland. Head Neck 2002;24:417–422. doi:10.1002/hed.10063.

    Article  PubMed  Google Scholar 

  7. O’Brien CJ, McNeil EB, McMahon JD, et al. Incidence of cervical node involvement in metastatic cutaneous malignancy involving the parotid gland. Head Neck 2001;23:744–748. doi:10.1002/hed.1106.

    Article  PubMed  Google Scholar 

  8. Veness MJ, Palme CE, Smith M, et al. Cutaneous head and neck squamous cell carcinoma metastatic to cervical lymph nodes (nonparotid): a better outcome with surgery and adjuvant radiotherapy. Laryngoscope 2003;113:1827–1833. doi:10.1097/00005537-200310000-00031.

    Article  PubMed  Google Scholar 

  9. Brantsch KD, Meisner C, Schonfisch B, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol 2008;9:713–720. doi:10.1016/S1470-2045(08)70178-5.

    Article  PubMed  Google Scholar 

  10. Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med 2001;344:975–983. doi:10.1056/NEJM200103293441306.

    Article  PubMed  CAS  Google Scholar 

  11. Bordea C, Wojnarowska F, Millard PR, et al. Skin cancers in renal-transplant recipients occur more frequently than previously recognized in a temperate climate. Transplantation 2004;77:574–579. doi:10.1097/01.TP.0000108491.62935.DF.

    Article  PubMed  CAS  Google Scholar 

  12. Hess SD, Schmults C: The clinical presentation and diagnosis of skin cancer in organ transplant recipients. In Skin Disease in Organ Transplantation. Edited by Otley C, Stasko T. Chapter 22, Cambridge; 2008

  13. Bichakjian CK, Lowe L, Lao CD, et al. Merkel cell carcinoma: critical review with guidelines for multidisciplinary management. Cancer 2007;110:1–12. doi:10.1002/cncr.22765.

    Article  PubMed  Google Scholar 

  14. Mullen JT, Feng L, Xing Y, et al.: Invasive squamous cell carcinoma of the skin: defining a high-risk group. Ann Surg Oncol 2006, 13:902–909

    Google Scholar 

  15. Marcen R, Pascual J, Tato AM, et al. Influence of immunosuppression on the prevalence of cancer after kidney transplantation. Transplant Proc 2003;35:1714–1716. doi:10.1016/S0041-1345(03)00669-9.

    Article  PubMed  CAS  Google Scholar 

  16. Ong CS, Keogh AM, Kossard S, et al. Skin cancer in Australian heart transplant recipients. J Am Acad Dermatol 1999;40:27–34. doi:10.1016/S0190-9622(99)70525-6.

    Article  PubMed  CAS  Google Scholar 

  17. Neville JA, Welch E, Leffell DJ. Management of nonmelanoma skin cancer in 2007. Nat Clin Pract Oncol 2007;4:462–469. doi:10.1038/ncponc0883.

    Article  PubMed  Google Scholar 

  18. Nouri K, Rivas MP. A primer of Mohs micrographic surgery: common indications. Skinmed 2004;3:191–196. doi:10.1111/j.1540-9740.2004.02458.x.

    Article  PubMed  Google Scholar 

  19. Clayton AS, Stasko T. Treatment of nonmelanoma skin cancer in organ transplant recipients: review of responses to a survey. J Am Acad Dermatol 2003;49:413–6. doi:10.1067/S0190-9622(03)01835-8.

    Article  PubMed  Google Scholar 

  20. Miller SJ, Alam M, Andersen J, et al. Basal cell and squamous cell skin cancers. J Natl Compr Canc Netw 2007;5:506–529.

    PubMed  Google Scholar 

  21. Liégeois NJ, et al.: Communication DLp. (in pre- paration)

  22. http://www.nccn.org/

  23. Audet N, Palme CE, Gullane PJ, et al. Cutaneous metastatic squamous cell carcinoma to the parotid gland: analysis and outcome. Head Neck 2004;26:727–732. doi:10.1002/hed.20048.

    Article  PubMed  Google Scholar 

  24. Stanley MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 2002;27:571–577. doi:10.1046/j.1365-2230.2002.01151.x.

    Article  PubMed  CAS  Google Scholar 

  25. Vidal D, Matias-Guiu X, Alomar A. Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis. Br J Dermatol 2004;151:656–662. doi:10.1111/j.1365-2133.2004.06094.x.

    Article  PubMed  CAS  Google Scholar 

  26. Prinz BM, Hafner J, Dummer R, et al. Treatment of Bowen’s disease with imiquimod 5% cream in transplant recipients. Transplantation 2004;77:790–791. doi:10.1097/01.TP.0000113445.02908.06.

    Article  PubMed  Google Scholar 

  27. Smith KJ, Germain M, Skelton H. Squamous cell carcinoma in situ (Bowen’s disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy. Dermatol Surg 2001;27:561–564. doi:10.1046/j.1524-4725.2001.00149.x.

    Article  PubMed  CAS  Google Scholar 

  28. Ulrich C, Bichel J, Euvrard S, et al. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol 2007;157 Suppl 2:25–31.

    Article  PubMed  CAS  Google Scholar 

  29. De Graaf YG, Euvrard S, Bouwes Bavinck JN. Systemic and topical retinoids in the management of skin cancer in organ transplant recipients. Dermatol Surg 2004;30:656–661. doi:10.1111/j.1524-4725.2004.30152.x.

    Article  PubMed  Google Scholar 

  30. Epstein E. Fluorouracil paste treatment of thin basal cell carcinomas. Arch Dermatol 1985;121:207–213. doi:10.1001/archderm.121.2.207.

    Article  PubMed  CAS  Google Scholar 

  31. Klostermann GF. Effects of 5-fluorouracil (5-FU) ointment on normal and diseased skin. Histological findings and deep action. Dermatologica 1970;140:Suppl 1:47–54.

    Article  PubMed  Google Scholar 

  32. Gross K, Kircik L, Kricorian G. 5% 5-fluorouracil cream for the treatment of small superficial basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction. Dermatol Surg 2007;33:433–439; discussion 440. doi:10.1111/j.1524-4725.2007.33090.x.

    Article  PubMed  CAS  Google Scholar 

  33. Chen K, Craig JC, Shumack S. Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials. Br J Dermatol 2005;152:518–523. doi:10.1111/j.1365-2133.2005.06347.x.

    Article  PubMed  CAS  Google Scholar 

  34. Kovach BT, Sams HH, Stasko T. Systemic strategies for chemoprevention of skin cancers in transplant recipients. Clin Transplant 2005;19:726–734.

    PubMed  Google Scholar 

  35. Otley CC, Stasko T, Tope WD, Lebwohl M. Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects. Dermatol Surg 2006;32:562–568. doi:10.1111/j.1524-4725.2006.32115.x.

    Article  PubMed  CAS  Google Scholar 

  36. Otley CC, Griffin MD, Charlton MR, Edwards BS, Neuburg M, Stasko T. Reduction of immunosuppression for transplant-associated skin cancer: thresholds and risks. Br J Dermatol 2007;157:1183–1188. doi:10.1111/j.1365-2133.2007.08203.x.

    Article  PubMed  CAS  Google Scholar 

  37. Otley CC, Berg D, Ulrich C, et al. Reduction of immunosuppression for transplant-associated skin cancer: expert consensus survey. Br J Dermatol 2006;154:395–400. doi:10.1111/j.1365-2133.2005.07087.x.

    Article  PubMed  CAS  Google Scholar 

  38. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 2004;91:1420–1424. doi:10.1038/sj.bjc.6602162.

    Article  PubMed  CAS  Google Scholar 

  39. Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005;80:883-889. doi:10.1097/01.TP.0000184006.43152.8D.

    Article  PubMed  CAS  Google Scholar 

  40. Kahan BD, Knight R, Schoenberg L, et al. Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience. Transplant Proc 2003;35:25S–34S. doi:10.1016/S0041-1345(03)00351-8.

    Article  PubMed  CAS  Google Scholar 

  41. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004;18:446–9. doi:10.1111/j.1399-0012.2004.00188.x.

    Article  PubMed  Google Scholar 

  42. Sumaira A: Skin cancer prevention and photoprotection in organ transplant. In Skin Disease in Organ Transplantation. Edited by Otley C, Stasko T. Chapter 46, Cambridge; 2008

Download references

Author information

Authors and Affiliations

  1. Johns Hopkins University, Baltimore, MD, USA

    M. J. Patel MD & N. J. Liégeois MD, PhD

Authors
  1. M. J. Patel MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. J. Liégeois MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. J. Liégeois MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Patel, M.J., Liégeois, N.J. Skin Cancer and the Solid Organ Transplant Recipient. Curr. Treat. Options in Oncol. 9, 251–258 (2008). https://doi.org/10.1007/s11864-008-0082-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-008-0082-0

Keywords

Search

Navigation